Literature DB >> 17534898

Pancreatic cancer microenvironment.

Jörg Kleeff1, Philipp Beckhove, Irene Esposito, Stephan Herzig, Peter E Huber, J Matthias Löhr, Helmut Friess.   

Abstract

Pancreatic ductal adenocarcinoma remains an extremely aggressive malignancy that is virtually therapy-resistant and has therefore one of the worst prognoses of all human cancers. The focus of research, which had been placed mostly on genetic and epigenetic alterations of the cancer cells themselves, has shifted gradually towards the microenvironment. The cancer microenvironment consists of various components, including fibroblasts, endothelial cells, immune cells, and endocrine cells, that interact with each other and the cancer cells in a complex fashion. This interplay has implications for pancreatic cancer cell growth, migration and invasion, angiogenesis, and immunological recognition of cancer cells. Evidence is accumulating that the cancer microenvironment plays an active role in disease progression, and efforts are being made to target this interplay between cancer cells and host cells to improve the outcome of this deadly disease.

Entities:  

Mesh:

Year:  2007        PMID: 17534898     DOI: 10.1002/ijc.22871

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  80 in total

1.  Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer.

Authors:  Daniel Delitto; Chelsey Perez; Song Han; David H Gonzalo; Kien Pham; Andrea E Knowlton; Christina L Graves; Kevin E Behrns; Lyle L Moldawer; Ryan M Thomas; Chen Liu; Thomas J George; Jose G Trevino; Shannon M Wallet; Steven J Hughes
Journal:  Cancer Immunol Immunother       Date:  2015-09-30       Impact factor: 6.968

2.  Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer.

Authors:  Dong Tang; Jun Gao; Sen Wang; Zhongxu Yuan; Nianyuan Ye; Yang Chong; Chuanqi Xu; Xuetong Jiang; Bin Li; Wei Yin; Yi Miao; Daorong Wang; Kuirong Jiang
Journal:  Tumour Biol       Date:  2015-03-01

3.  In vitro models of pancreatic cancer for translational oncology research.

Authors:  Georg Feldmann; Sherri Rauenzahn; Anirban Maitra
Journal:  Expert Opin Drug Discov       Date:  2009-04-01       Impact factor: 6.098

Review 4.  Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer.

Authors:  M Mimeault; S K Batra
Journal:  Gut       Date:  2008-10       Impact factor: 23.059

5.  Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers.

Authors:  Erik S Knudsen; Paris Vail; Uthra Balaji; Hoai Ngo; Ihab W Botros; Vladimir Makarov; Nadeem Riaz; Vinod Balachandran; Steven Leach; Debrah M Thompson; Timothy A Chan; Agnieszka K Witkiewicz
Journal:  Clin Cancer Res       Date:  2017-03-27       Impact factor: 12.531

Review 6.  Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy.

Authors:  Emma Kipps; Kate Young; Naureen Starling
Journal:  Ther Adv Med Oncol       Date:  2017-03-01       Impact factor: 8.168

7.  A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Authors:  Bridget P Keenan; Yvonne Saenger; Michel I Kafrouni; Ashley Leubner; Peter Lauer; Anirban Maitra; Agnieszka A Rucki; Andrew J Gunderson; Lisa M Coussens; Dirk G Brockstedt; Thomas W Dubensky; Raffit Hassan; Todd D Armstrong; Elizabeth M Jaffee
Journal:  Gastroenterology       Date:  2014-03-06       Impact factor: 22.682

8.  Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

Authors:  T Dragovich; D Laheru; F Dayyani; V Bolejack; L Smith; J Seng; H Burris; P Rosen; M Hidalgo; P Ritch; A F Baker; N Raghunand; J Crowley; D D Von Hoff
Journal:  Cancer Chemother Pharmacol       Date:  2014-06-18       Impact factor: 3.333

9.  A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer.

Authors:  Rohit Chugh; Veena Sangwan; Satish P Patil; Vikas Dudeja; Rajinder K Dawra; Sulagna Banerjee; Robert J Schumacher; Bruce R Blazar; Gunda I Georg; Selwyn M Vickers; Ashok K Saluja
Journal:  Sci Transl Med       Date:  2012-10-17       Impact factor: 17.956

10.  Non-redundant role for IL-12 and IL-27 in modulating Th2 polarization of carcinoembryonic antigen specific CD4 T cells from pancreatic cancer patients.

Authors:  Elena Tassi; Marco Braga; Renato Longhi; Francesca Gavazzi; Giorgio Parmiani; Valerio Di Carlo; Maria Pia Protti
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.